Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
Subscribe To Our Newsletter & Stay Updated
